HETEROCYCLIC COMPOUNDS AS AGONISTS OF THE ACTIVATING RECEPTOR EXPRESSED IN MYELOID CELLS 2 AND METHODS OF USE.
MX435197BActive Publication Date: 2026-06-12AMGEN INC +1
Patent Information
- Authority / Receiving Office
- MX · MX
- Patent Type
- Patents
- Current Assignee / Owner
- AMGEN INC
- Filing Date
- 2022-11-03
- Publication Date
- 2026-06-12
AI Technical Summary
Technical Problem
Current treatments for neurological diseases such as Alzheimer's and Parkinson's lack effective activators for the TREM2 receptor, which is crucial for microglial responses to CNS pathology, leading to unmitigated disease progression and societal burden.
Method used
Development of heterocyclic compounds that act as agonists of the TREM2 receptor, activating it to modulate microglial responses and potentially treat or prevent conditions associated with TREM2 loss of function, including neurological diseases.
Benefits of technology
The compounds effectively activate TREM2, offering therapeutic potential for conditions like Alzheimer's, Parkinson's, and other neurodegenerative disorders by enhancing microglial responses to CNS pathology.
✦ Generated by Eureka AI based on patent content.
Abstract
This description provides compounds of Formula I, useful for the activation of the activation receptor expressed in myeloid cells 2 ("TREM2"). (see formula) This description also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for the treatment of, for example, a neurodegenerative disorder. In addition, the description provides intermediates useful in the synthesis of compounds of Formula I.
Need to check novelty before this filing date? Find Prior Art